<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">35546175</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures.</ArticleTitle>
        <Pagination>
          <StartPage>7743</StartPage>
          <MedlinePgn>7743</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">7743</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-11857-7</ELocationID>
        <Abstract>
          <AbstractText>Data concerning the efficacy of SARS-CoV-2 vaccines in patients with non-oncological hematologic conditions are lacking. These include autoimmune cytopenias (autoimmune hemolytic anemia AIHA, immune thrombocytopenia ITP, and autoimmune neutropenia), and bone marrow failure syndromes (aplastic anemia, low risk myelodysplastic syndromes, and paroxysmal nocturnal hemoglobinuria). These conditions may relapse/reactivate after COVID-19 infection and vaccine. Moreover, they are mainly handled with immunosuppressive drugs that may hamper the response to vaccine. In this study, we prospectively evaluated the rate of seroconversion after mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias or bone marrow failure syndrome after 2 ± 1 months from the last vaccine dose. Overall, 149 patients were tested and 135 (91%) seroconverted. The highest proportion of non-responders was observed in Evans syndrome (association of ITP and AIHA) and warm AIHA patients (p = 0.001), in those with lower levels of baseline serum IgG (p = 0.008), and in patients on active therapy with steroids (p = 0.03) who also had lower anti-Spike titers. The latter were inversely related with age, and a positively with lymphocyte counts. Additionally, patients who had received rituximab within 12 months from vaccination showed higher rates of non-response (p = 0.03) as compared to those treated before. Contrarily, cyclosporine alone, complement inhibitors, and bone marrow stimulating agents had no detrimental effect on seroconversion. These data suggest maintaining high vigilance and adherence to preventive/protective measures in this population since a proportion of cases may not respond or exhibit low anti-Spike titers.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fattizzo</LastName>
            <ForeName>Bruno</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20100, Milan, Italy. bruno.fattizzo@unimi.it.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Oncohematology, University of Milan, Milan, Italy. bruno.fattizzo@unimi.it.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bortolotti</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20100, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology and Oncohematology, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giannotta</LastName>
            <ForeName>Juri Alessandro</ForeName>
            <Initials>JA</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20100, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Consonni</LastName>
            <ForeName>Dario</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cantoni</LastName>
            <ForeName>Silvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Ematologia e Oncologia, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barcellini</LastName>
            <ForeName>Wilma</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, via Francesco Sforza 35, 20100, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014612">Vaccines</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000080983" MajorTopicYN="N">Bone Marrow Failure Disorders</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010198" MajorTopicYN="Y">Pancytopenia</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069078" MajorTopicYN="N">Seroconversion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>1</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35546175</ArticleId>
        <ArticleId IdType="pmc">PMC9093558</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-022-11857-7</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-022-11857-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031–1033. doi: 10.1016/j.ccell.2021.07.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2021.07.012</ArticleId>
            <ArticleId IdType="pmc">PMC8295014</ArticleId>
            <ArticleId IdType="pubmed">34331856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, Naumovas D, Banys V, Pečeliūnas V, Beinortas T, Griškevičius L. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: A national prospective cohort study. Lancet Haematol. 2021;8(8):e583–e592. doi: 10.1016/S2352-3026(21)00169-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2352-3026(21)00169-1</ArticleId>
            <ArticleId IdType="pmc">PMC8253543</ArticleId>
            <ArticleId IdType="pubmed">34224668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, Eshagh D, Adotevi O, Laheurte C, Ricard L, Dulery R, Stocker N, van de Wyngaert Z, Genthon A, Banet A, Memoli M, Ikhlef S, Sestilli S, Vekhof A, Brissot E, Marjanovic Z, Chantran Y, Cuervo N, Ballot E, Morand-Joubert L, Mohty M. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021;11(8):142. doi: 10.1038/s41408-021-00534-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41408-021-00534-z</ArticleId>
            <ArticleId IdType="pmc">PMC8353615</ArticleId>
            <ArticleId IdType="pubmed">34376633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, Tabib Y, Cohen YC, Benyamini N, Beyar-Katz O, Neaman M, Vitkon R, Keren-Khadmy N, Levin M, Herishanu Y, Avivi I. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5(16):3053–3061. doi: 10.1182/bloodadvances.2021005094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2021005094</ArticleId>
            <ArticleId IdType="pmc">PMC8362658</ArticleId>
            <ArticleId IdType="pubmed">34387648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehmsen S, Asmussen A, Jeppesen SS, Nilsson AC, Østerlev S, Vestergaard H, Justesen US, Johansen IS, Frederiksen H, Ditzel HJ. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034–1036. doi: 10.1016/j.ccell.2021.07.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2021.07.016</ArticleId>
            <ArticleId IdType="pmc">PMC8313483</ArticleId>
            <ArticleId IdType="pubmed">34348121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths EA, Segal BH. Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution. Cancer Cell. 2021;39(8):1045–1047. doi: 10.1016/j.ccell.2021.07.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2021.07.001</ArticleId>
            <ArticleId IdType="pmc">PMC8253695</ArticleId>
            <ArticleId IdType="pubmed">34242573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellini W, Giannotta JA, Fattizzo B. Are patients with autoimmune cytopenias at higher risk of COVID-19 pneumonia? The experience of a reference center in northern Italy and review of the literature. Front. Immunol. 2021;11:609198. doi: 10.3389/fimmu.2020.609198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.609198</ArticleId>
            <ArticleId IdType="pmc">PMC7870679</ArticleId>
            <ArticleId IdType="pubmed">33574816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo B, Giannotta JA, Cecchi N, Barcellini W. SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor. Am. J. Hematol. 2021;96(9):E344–E346. doi: 10.1002/ajh.26262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.26262</ArticleId>
            <ArticleId IdType="pmc">PMC8212106</ArticleId>
            <ArticleId IdType="pubmed">34057236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo B, Pasquale R, Bellani V, Barcellini W, Kulasekararaj AG. Complement mediated hemolytic anemias in the COVID-19 era: Case series and review of the literature. Front. Immunol. 2021;12:791429. doi: 10.3389/fimmu.2021.791429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.791429</ArticleId>
            <ArticleId IdType="pmc">PMC8655106</ArticleId>
            <ArticleId IdType="pubmed">34899761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellini W, Fattizzo B, Giannotta JA, Quattrocchi L, Aydin S, Barone F, Carbone C, Pomponi F, Metafuni E, Beggiato E, Sica S, Di Bona E, Lanza F, Notaro R, Iori AP. COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: An Italian multicentre survey. Br. J. Haematol. 2021;194(5):854–856. doi: 10.1111/bjh.17558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.17558</ArticleId>
            <ArticleId IdType="pmc">PMC8239635</ArticleId>
            <ArticleId IdType="pubmed">34036575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo B, Giannotta JA, Cecchi N, Barcellini W. SARS-CoV-2 vaccination in patients with autoimmune cytopenias: The experience of a reference center. Am. J. Hematol. 2021;96(11):E413–E416. doi: 10.1002/ajh.26345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.26345</ArticleId>
            <ArticleId IdType="pmc">PMC8646755</ArticleId>
            <ArticleId IdType="pubmed">34478178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, Jilma B, Kuter DJ, Michel M, Montillo M, Röth A, Zeerleder SS, Berentsen S. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. doi: 10.1016/j.blre.2019.100648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.blre.2019.100648</ArticleId>
            <ArticleId IdType="pubmed">31839434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, Kühne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi: 10.1182/bloodadvances.2019000966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2019000966</ArticleId>
            <ArticleId IdType="pmc">PMC6963252</ArticleId>
            <ArticleId IdType="pubmed">31794604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U, ESMO Guidelines Committee  Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2021;32(2):142–156. doi: 10.1016/j.annonc.2020.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.annonc.2020.11.002</ArticleId>
            <ArticleId IdType="pubmed">33221366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JC, British Society for Standards in Haematology  Guidelines for the diagnosis and management of adult aplastic anaemia. Br. J. Haematol. 2016;172(2):187–207. doi: 10.1111/bjh.13853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.13853</ArticleId>
            <ArticleId IdType="pubmed">26568159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi A, Consonni D, Oggioni M, Bono P, Uceda Renteria S, Piatti A, Pesatori AC, Castaldi S, Muscatello A, Riboldi L, Ceriotti F, Bandera A, Gori A. SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals. J. Infect. Public Health. 2021;14(8):1120–1122. doi: 10.1016/j.jiph.2021.07.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiph.2021.07.005</ArticleId>
            <ArticleId IdType="pmc">PMC8285930</ArticleId>
            <ArticleId IdType="pubmed">34293641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boekel L, Steenhuis M, Hooijberg F, et al.  Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: A substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):e778–e788. doi: 10.1016/S2665-9913(21)00222-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(21)00222-8</ArticleId>
            <ArticleId IdType="pmc">PMC8346242</ArticleId>
            <ArticleId IdType="pubmed">34396154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferri C, Ursini F, Gragnani L, et al.  Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. J. Autoimmun. 2021;125:102744. doi: 10.1016/j.jaut.2021.102744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2021.102744</ArticleId>
            <ArticleId IdType="pmc">PMC8577991</ArticleId>
            <ArticleId IdType="pubmed">34781162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prendecki M, Clarke C, Edwards H, et al.  Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann. Rheum. Dis. 2021;80(10):1322–1329. doi: 10.1136/annrheumdis-2021-220626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2021-220626</ArticleId>
            <ArticleId IdType="pmc">PMC8350975</ArticleId>
            <ArticleId IdType="pubmed">34362747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanguay M, Boutin M, Laumaea A, Salaciak M, Mendoza A, Cassis C, Ajjamada L, Assouline S, Patenaude F, Clark MW, Finzi A, Johnson NA. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine. 2022;40(9):1203–1207. doi: 10.1016/j.vaccine.2022.01.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2022.01.040</ArticleId>
            <ArticleId IdType="pmc">PMC8784616</ArticleId>
            <ArticleId IdType="pubmed">35105492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fattizzo, B. et al. Seroconversion to mRNA SARS-CoV-2 vaccines in hematologic patients. Front. Immunol. (2022) (in Press)</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
